Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4189B | ISIN: US02262M6057 | Ticker-Symbol: 9ZT0
München
06.06.25 | 08:29
3,400 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALZAMEND NEURO INC Chart 1 Jahr
5-Tage-Chart
ALZAMEND NEURO INC 5-Tage-Chart

Aktuelle News zur ALZAMEND NEURO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.05.Alzamend Neuro (ALZN) Stock Surges On AL001 Phase II Trial Milestone2
ALZAMEND NEURO Aktie jetzt für 0€ handeln
29.05.Alzamend Neuro begins phase II trial for novel lithium delivery system1
29.05.Alzamend Neuro beginnt Phase-II-Studie für neuartiges Lithium-Verabreichungssystem3
19.05.Alzamend beginnt Phase-II-Studie für neuartige Lithium-Therapie4
19.05.Alzamend begins phase II trial for novel lithium therapy1
13.05.EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants2
08.05.Alzamend Neuro, Inc. - 8-K, Current Report2
08.05.Alzamend Neuro to conduct reverse stock split3
08.05.Alzamend Neuro announces reverse stock split to meet Nasdaq requirements2
08.05.Alzamend Neuro, Inc.: Alzamend Neuro Announces Reverse Stock Split55ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel products for the...
► Artikel lesen
07.05.EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program1
25.04.Alzamend Neuro, Inc. - 8-K, Current Report5
27.03.Alzamend Neuro, Inc. - S-1/A, General form for registration of securities3
25.03.Alzamend Neuro, Inc.: Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital115ATLANTA, March 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's...
► Artikel lesen
18.03.Alzamend Neuro, Inc.: Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital176Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in MDD subjects ATLANTA, March...
► Artikel lesen
11.03.EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits3
10.03.Alzamend Neuro, Inc. - 10-Q, Quarterly Report5
04.03.Alzamend Neuro, Inc.: Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital134ATLANTA, March 04, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's...
► Artikel lesen
28.02.Alzamend Neuro, Inc. - 8-K, Current Report-
25.02.EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 20255
Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1